MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/ajh.27231

Медицинская библиотека · American journal of hematology · 2024

Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real-world data from eight US academic centers.

Abaza Yasmin, Winer Eric S, Murthy Guru Subramanian Guru, Shallis Rory M, Matthews Andrew H, Badar Talha, Geramita Emily M, Kota Vamsi K, Swaroop Alok, Doukas Peter, Bradshaw Danielle, Helenowski Irene B, Liu Yingzhe, Zhang Hui, Im Annie, Litzow Mark R, Perl Alexander E, Atallah Ehab, Altman Jessica K

Многоцентровое исследованиеСтатьяПеревод в очереди

Аннотация

Venetoclax (VEN) combined with hypomethylating agents (HMAs) is the standard of care for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) unfit for intensive chemotherapy. To date, real-world data published on HMAs plus VEN have been either single-center studies or using community-based electronic databases with limited details on mutational landscape, tolerability, and treatment patterns in elderly patients. Therefore, we conducted a multicenter retrospective study to assess the real-world experience of 204 elderly patients (≥75 years) with newly diagnosed AML treated with HMAs plus VEN from eight academic centers in the United States. Overall, 64 patients achieved complete remission (CR; 38%) and 43 CR with incomplete count recovery (CRi; 26%) for a CR/CRi rate of 64%, with a median duration of response of 14.2 months (95% CI: 9.43, 22.1). Among responders, 63 patients relapsed (59%) with median overall survival (OS) after relapse of 3.4 months (95% CI, 2.4, 6.7). Median OS for the entire population was 9.5 months (95% CI, 7.85-13.5), with OS significantly worse among patients with TP53-mutated AML (2.5 months) and improved in patients harboring NPM1, IDH1, and IDH2 mutations (13.5, 18.3, and 21.1 months, respectively). The 30-day and 60-day mortality rates were 9% and 19%, respectively. In conclusion, HMAs plus VEN yielded high response rates in elderly patients with newly diagnosed AML. The median OS was inferior to that reported in the VIALE-A trial. Outcomes are dismal after failure of HMAs plus VEN, representing an area of urgent unmet clinical need.

Для цитирования: Abaza Yasmin, Winer Eric S, Murthy Guru Subramanian Guru, Shallis Rory M, Matthews Andrew H, Badar Talha, Geramita Emily M, Kota Vamsi K, Swaroop Alok, Doukas Peter, Bradshaw Danielle, Helenowski Irene B, Liu Yingzhe, Zhang Hui, Im Annie, Litzow Mark R, Perl Alexander E, Atallah Ehab, Altman Jessica K. Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real-world data from eight US academic centers.. American journal of hematology. 2024. DOI: 10.1002/ajh.27231.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.